Virological and clinical outcomes in outpatients treated with baloxavir or oseltamivir: A Japanese multicenter study in the 2019–2020 influenza season-Reference-Cited by-同舟云学术

Virological and clinical outcomes in outpatients treated with baloxavir or oseltamivir: A Japanese multicenter study in the 2019–2020 influenza season

Published:2021-08 Issue: Volume:192 Page:105092
ISSN:0166-3542
Container-title:Antiviral Research
language:en
Short-container-title:Antiviral Research

Author:

Chong Yong,Kawai Naoki,Tani Naoki,Bando Takuma,Takasaki Yoshio,Shindo Shizuo,Ikematsu Hideyuki

Funder

Shionogi

Publisher

Elsevier BV

Subject

Virology,Pharmacology

Reference13 articles.

1. Baloxavir marboxil single-dose treatment in influenza-infected children: a randomized, double-blind, active controlled phase 3 safety and efficacy trial (miniSTONE-2);Baker;Pediatr. Infect. Dis. J.,2020

2. Baloxavir marboxil for uncomplicated influenza in adults and adolescents;Hayden;N. Engl. J. Med.,2018

3. Baloxavir marboxil in Japanese pediatric patients with influenza: safety and clinical and virologic outcomes;Hirotsu;Clin. Infect. Dis.,2019

4. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate in the 2016/17 Japanese influenza season; comparison with the 2011/12 to 2015/16 seasons;Ikematsu;J. Infect. Chemother.,2018

5. Duration of fever and PA/I38X-substituted virus emergence in patients treated with baloxavir in the 2018-2019 influenza season;Ikematsu;J. Infect. Chemother.,2020

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Duration of fever in children infected with influenza A(H1N1)pdm09, A(H3N2) or B virus and treated with baloxavir marboxil, oseltamivir, laninamivir, or zanamivir in Japan during the 2012–2013 and 2019–2020 influenza seasons;Antiviral Research;2024-08

2. Comparative Effectiveness of Baloxavir Marboxil and Oseltamivir Treatment in Reducing Household Transmission of Influenza: A Post Hoc Analysis of the BLOCKSTONE Trial;Influenza and Other Respiratory Viruses;2024-05

3. Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for A(H3N2) influenza: A multicenter study of the 2022–2023 season;Antiviral Research;2024-04

4. Discovery of ligustrazine and chalcone derivatives as novel viral nucleoprotein nuclear export inhibitors against influenza viruses;Journal of Medical Virology;2023-07

5. Factors associated with viral RNA shedding and evaluation of potential viral infectivity at returning to school in influenza outpatients after treatment with baloxavir marboxil and neuraminidase inhibitors during 2013/2014–2019/2020 seasons in Japan: an observational study;BMC Infectious Diseases;2023-03-29